checkAd

     184  0 Kommentare Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology to SAFELY and EFFECTIVELY Vaccinate Children and Pregnant Women

    NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Last Chance for Children’s (LCFC) Mission is to help save children’s lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our efforts to help eradicate this virus so we could safely and effectively vaccinate children in need.

    Why do we need a COVID-19 Vaccine for Children and Pregnant Women?

    Children’s lives have been completely disrupted by the coronavirus pandemic. To date, none of the vaccines against COVID-19 are approved by the FDA for use in children under 12 years old or pregnant women.

    The current vaccines approved for emergency use did not enroll children nor pregnant women in their original clinical trials, so data on the safety of these vaccines in these populations is sorely lacking. As pregnant women have a 70% increased risk of severe COVID disease, a safe vaccine is desperately needed. And even though children do not generally get severe COVID, the lack of a vaccine is keeping kids out of school, limiting social interaction, and potentially leaving many kids behind. Plus, if we want to reach herd immunity necessary to eradicate the pandemic, we need to vaccinate kids.

    Furthermore, most of these vaccines are based on gene therapy using RNA and DNA vectors that have unknown questions on duration of protection and long-term safety. The NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 vaccine is based on natural amino acids using sequences that mimic the coronavirus spike and structural proteins, and selectively regulate select immune responses that are targeted specifically against the SARS-CoV-2 virus without using genetic material.

    Generex Biotechnology Corporation’s majority owned public company NuGenerex Immuno-Oncology, Inc. (“NGIO”) is developing the Ii-Key-SARS-CoV-2 vaccine with a special emphasis on the development of a safe and effective vaccine for the pediatric population and for pregnant women, populations with significant unmet need in the COVID vaccine race. The company has completed GMP manufacturing of its Ii-Key-SARS-CoV-2 peptides and plans to submit its FDA IND to initiate clinical trials as soon as possible. NGIO’s goal is to start the pediatric clinical trials by the Fall of 2021.

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology to SAFELY and EFFECTIVELY Vaccinate Children and Pregnant Women NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) - Last Chance for Children’s (LCFC) Mission is to help save children’s lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our efforts to help eradicate this virus so we could …